Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Angiogenesis
Published in: Angiogenesis 2/2009

01-06-2009 | Review Paper

Fibronectins in vascular morphogenesis

Authors: Sophie Astrof, Richard O. Hynes

Published in: Angiogenesis | Issue 2/2009

Login to get access

Abstract

Fibronectin is an extracellular matrix protein found only in vertebrate organisms containing endothelium-lined vasculature and is required for cardiovascular development in fish and mice. Fibronectin and its splice variants containing EIIIA and EIIIB domains are highly upregulated around newly developing vasculature during embryogenesis and in pathological conditions including atherosclerosis, cardiac hypertrophy, and tumorigenesis. However, their molecular roles in these processes are not entirely understood. We review genetic studies examining functions of fibronectin and its splice variants during embryonic cardiovascular development, and discuss potential roles of fibronectin in vascular disease and tumor angiogenesis.
Literature
1.
Coultas L et al (2005) Endothelial cells and VEGF in vascular development. Nature 438:937–945PubMed
2.
Hodivala-Dilke K (2008) Alphavbeta3 integrin and angiogenesis: a moody integrin in a changing environment. Curr Opin Cell Biol 20:514–519PubMed
3.
Hynes RO (2007) Cell-matrix adhesion in vascular development. J Thromb Haemost 5(Suppl 1):32–40PubMed
4.
Armulik A et al (2005) Endothelial/pericyte interactions. Circ Res 97:512–523PubMed
5.
Bergers G, Song S (2005) The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 7:452–464PubMed
6.
von Tell D et al (2006) Pericytes and vascular stability. Exp Cell Res 312:623–629
7.
George EL et al (1997) Fibronectins are essential for heart and blood vessel morphogenesis but are dispensable for initial specification of precursor cells. Blood 90:3073–3081PubMed
8.
George EL et al (1993) Defects in mesoderm, neural tube and vascular development in mouse embryos lacking fibronectin. Development 119:1079–1091PubMed
9.
Georges-Labouesse EN et al (1996) Mesodermal development in mouse embryos mutant for fibronectin. Dev Dyn 207:145–156PubMed
10.
Francis SE et al (2002) Central roles of alpha5beta1 integrin and fibronectin in vascular development in mouse embryos and embryoid bodies. Arterioscler Thromb Vasc Biol 22:927–933PubMed
11.
Lucitti JL et al (2007) Vascular remodeling of the mouse yolk sac requires hemodynamic force. Development 134:3317–3326PubMed
12.
Astrof S et al (2007) Heart development in fibronectin-null mice is governed by a genetic modifier on chromosome four. Mech Dev 124:551–558PubMed
13.
Trinh LA, Stainier DY (2004) Fibronectin regulates epithelial organization during myocardial migration in zebrafish. Dev Cell 6:371–382PubMed
14.
Koshida S et al (2005) Integrinalpha5-dependent fibronectin accumulation for maintenance of somite boundaries in zebrafish embryos. Dev Cell 8:587–598PubMed
15.
Marsden M, DeSimone DW (2001) Regulation of cell polarity, radial intercalation and epiboly in Xenopus: novel roles for integrin and fibronectin. Development 128:3635–3647PubMed
16.
Katsuno T et al (2008) Deficiency of zonula occludens-1 causes embryonic lethal phenotype associated with defected yolk sac angiogenesis and apoptosis of embryonic cells. Mol Biol Cell 19:2465–2475PubMed
17.
Ikenouchi J et al (2007) Requirement of ZO-1 for the formation of belt-like adherens junctions during epithelial cell polarization. J Cell Biol 176:779–786PubMed
18.
Umeda K et al (2006) ZO-1 and ZO-2 independently determine where claudins are polymerized in tight-junction strand formation. Cell 126:741–754PubMed
19.
Buchner DA et al (2007) Pak2a mutations cause cerebral hemorrhage in redhead zebrafish. Proc Natl Acad Sci U S A 104:13996–14001PubMed
20.
Kamei M et al (2006) Endothelial tubes assemble from intracellular vacuoles in vivo. Nature 442:453–456PubMed
21.
Koh W et al (2008) Cdc42- and Rac1-mediated endothelial lumen formation requires Pak2, Pak4 and Par3, and PKC-dependent signaling. J Cell Sci 121:989–1001PubMed
22.
Giancotti FG, Tarone G (2003) Positional control of cell fate through joint integrin/receptor protein kinase signaling. Annu Rev Cell Dev Biol 19:173–206PubMed
23.
Hynes RO et al (2002) The diverse roles of integrins and their ligands in angiogenesis. Cold Spring Harb Symp Quant Biol 67:143–153PubMed
24.
Yang JT, Hynes RO (1996) Fibronectin receptor functions in embryonic cells deficient in alpha 5 beta 1 integrin can be replaced by alpha V integrins. Mol Biol Cell 7:1737–1748PubMed
25.
Taverna D, Hynes RO (2001) Reduced blood vessel formation and tumor growth in alpha5-integrin-negative teratocarcinomas and embryoid bodies. Cancer Res 61:5255–5261PubMed
26.
Aota S et al (1994) The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J Biol Chem 269:24756–24761PubMed
27.
Hynes RO (1990) Fibronectins. Springer-Verlag, New York
28.
Takahashi S et al (2007) The RGD motif in fibronectin is essential for development but dispensable for fibril assembly. J Cell Biol 178:167–178PubMed
29.
Bader BL et al (1998) Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins. Cell 95:507–519PubMed
30.
Grazioli A et al (2006) Defective blood vessel development and pericyte/pvSMC distribution in alpha 4 integrin-deficient mouse embryos. Dev Biol 293:165–177PubMed
31.
Wijelath ES et al (2002) Novel vascular endothelial growth factor binding domains of fibronectin enhance vascular endothelial growth factor biological activity. Circ Res 91:25–31PubMed
32.
Wijelath ES et al (2006) Heparin-II domain of fibronectin is a vascular endothelial growth factor-binding domain: enhancement of VEGF biological activity by a singular growth factor/matrix protein synergism. Circ Res 99:853–860PubMed
33.
Lee S et al (2005) Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors. J Cell Biol 169:681–691PubMed
34.
Carmeliet P et al (1999) Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188. Nat Med 5:495–502PubMed
35.
Maes C et al (2004) Soluble VEGF isoforms are essential for establishing epiphyseal vascularization and regulating chondrocyte development and survival. J Clin Invest 113:188–199PubMed
36.
Zhou X et al (2008) Fibronectin fibrillogenesis regulates three-dimensional neovessel formation. Genes Dev 22:1231–1243PubMed
37.
Bayless et al (2000) RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the alpha(v)beta(3) and alpha(5)beta(1) integrins. Am J Pathol 156:1673–1683PubMed
38.
McCarty JH et al (2002) Defective associations between blood vessels and brain parenchyma lead to cerebral hemorrhage in mice lacking alphav integrins. Mol Cell Biol 22:7667–7677PubMed
39.
Yang JT et al (1999) Overlapping and independent functions of fibronectin receptor integrins in early mesodermal development. Dev Biol 215:264–277PubMed
40.
Carlson TR et al (2008) Cell-autonomous requirement for beta1 integrin in endothelial cell adhesion migration and survival during angiogenesis in mice. Development 135:2193–2202PubMed
41.
Wierzbicka-Patynowski I, Schwarzbauer JE (2003) The ins and outs of fibronectin matrix assembly. J Cell Sci 116:3269–3276PubMed
42.
White ES et al (2008) New insights into form and function of fibronectin splice variants. J Pathol 216:1–14PubMed
43.
Astrof S et al (2007) Multiple cardiovascular defects caused by the absence of alternatively spliced segments of fibronectin. Dev Biol 311:11–24PubMed
44.
Dickson MC et al (1995) Defective haematopoiesis and vasculogenesis in transforming growth factor-beta 1 knock out mice. Development 121:1845–1854PubMed
45.
Ferrara N et al (1996) Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380:439–442PubMed
46.
Lee SH et al (2000) Maintenance of vascular integrity in the embryo requires signaling through the fibroblast growth factor receptor. J Biol Chem 275:33679–33687PubMed
47.
Suri C et al (1996) Requisite role of angiopoietin–1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 87:1171–1180PubMed
48.
Miyamoto S et al (1996) Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J Cell Biol 135:1633–1642PubMed
49.
Reinhart-King CA et al (2005) The dynamics and mechanics of endothelial cell spreading. Biophys J 89:676–689PubMed
50.
Davidson LA et al (2008) Live imaging of cell protrusive activity, and extracellular matrix assembly and remodeling during morphogenesis in the frog, Xenopus laevis. Dev Dyn 237:2684–2692PubMed
51.
Erickson HP (1994) Reversible unfolding of fibronectin type III and immunoglobulin domains provides the structural basis for stretch and elasticity of titin and fibronectin. Proc Natl Acad Sci U S A 91:10114–10118PubMed
52.
Liao YF et al (2002) The EIIIA segment of fibronectin is a ligand for integrins alpha 9beta 1 and alpha 4beta 1 providing a novel mechanism for regulating cell adhesion by alternative splicing. J Biol Chem 277:14467–14474PubMed
53.
Okamura Y et al (2001) The extra domain A of fibronectin activates toll-like receptor 4. J Biol Chem 276:10229–10233PubMed
54.
Shinde AV et al (2008) Identification of the peptide sequences within the EIIIA (EDA) segment of fibronectin that mediate integrin alpha9beta1-dependent cellular activities. J Biol Chem 283:2858–2870PubMed
55.
Huang XZ et al (2000) Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol Cell Biol 20:5208–5215PubMed
56.
Li S et al (2003) The serum response factor coactivator myocardin is required for vascular smooth muscle development. Proc Natl Acad Sci U S A 100:9366–9370PubMed
57.
Serini G et al (1998) The fibronectin domain ED-A is crucial for myofibroblastic phenotype induction by transforming growth factor-beta1. J Cell Biol 142:873–881PubMed
58.
High FA et al (2007) An essential role for Notch in neural crest during cardiovascular development and smooth muscle differentiation. J Clin Invest 117:353–363PubMed
59.
Hirschi et al (2003) Gap junction communication mediates transforming growth factor-{beta} activation and endothelial-induced mural cell differentiation. Circ Res 93:429–437PubMed
60.
Wurdak H et al (2005) Inactivation of TGF{beta} signaling in neural crest stem cells leads to multiple defects reminiscent of DiGeorge syndrome. Genes Dev 19:530–535PubMed
61.
Lindblom P et al (2003) Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall. Genes Dev 17:1835–1840PubMed
62.
Abramsson A et al (2003) Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 112:1142–1151PubMed
63.
Hellstrom M et al (1999) Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse. Development 126:3047–3055PubMed
64.
Majesky MW (2007) Developmental basis of vascular smooth muscle diversity. Arterioscler Thromb Vasc Biol 27:1248–1258PubMed
65.
Esner M et al (2006) Smooth muscle of the dorsal aorta shares a common clonal origin with skeletal muscle of the myotome. Development 133:737–749PubMed
66.
Snider P et al (2007) Cardiovascular development and the colonizing cardiac neural crest lineage. Scientific World J 7:1090–1113
67.
Ffrench-Constant C, Hynes RO (1988) Patterns of fibronectin gene expression and splicing during cell migration in chicken embryos. Development 104:369–382PubMed
68.
Carmeliet P (2003) Angiogenesis in health and disease. Nat Med 9:653–660PubMed
69.
Cascone I et al (2005) Stable interaction between alpha5beta1 integrin and Tie2 tyrosine kinase receptor regulates endothelial cell response to Ang–1. J Cell Biol 170:993–1004PubMed
70.
Sheppard J et al (1994) Expanding roles for alpha 4 integrin and its ligands in development. Cell Adhes Commun 2:27–43PubMed
71.
Vlahakis NE et al (2005) The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J Biol Chem 280:4544–4552PubMed
72.
Bergers G et al (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284:808–812PubMed
73.
Bergers G et al (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111:1287–1295PubMed
74.
Morikawa S et al (2002) Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 160:985–1000PubMed
75.
Benjamin LE, Keshet E (1997) Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci USA 94:8761–8766PubMed
76.
Sennino B et al (2007) Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Cancer Res 67:7358–7367PubMed
77.
Owens GK et al (2004) Molecular regulation of vascular smooth muscle cell differentiation in development and disease. Physiol Rev 84:767–801PubMed
78.
Dzau VJ et al (2002) Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies. Nat Med 8:1249–1256PubMed
79.
Glukhova MA et al (1989) Expression of extra domain A fibronectin sequence in vascular smooth muscle cells is phenotype dependent. J Cell Biol 109:357–366PubMed
80.
Rosamond W et al (2007) Heart disease and stroke statistics-2007 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 115:e69–e171PubMed
81.
Babaev VR et al (2008) Absence of regulated splicing of fibronectin EDA exon reduces atherosclerosis in mice. Atherosclerosis 197:534–540PubMed
82.
Tan MH et al (2004) Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis. Blood 104:11–18PubMed
83.
Dangas G, Kuepper F (2002) Cardiology patient page. Restenosis: repeat narrowing of a coronary artery: prevention and treatment. Circulation 105:2586–2587PubMed
84.
Dubin D et al (1995) Balloon catheterization induces arterial expression of embryonic fibronectins. Arterioscler Thromb Vasc Biol 15:1958–1967PubMed
85.
Samuel JL et al (1991) Accumulation of fetal fibronectin mRNAs during the development of rat cardiac hypertrophy induced by pressure overload. J Clin Invest 88:1737–1746PubMed
86.
Coito AJ et al (1997) Expression of fibronectin splicing variants in organ transplantation: a differential pattern between rat cardiac allografts and isografts. Am J Pathol 150:1757–1772PubMed
87.
Cai CL et al (2008) A myocardial lineage derives from Tbx18 epicardial cells. Nature 454:104–108PubMed
88.
Zhou B et al (2008) Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature 454:109–113PubMed
89.
Lepilina A et al (2006) A dynamic epicardial injury response supports progenitor cell activity during zebrafish heart regeneration. Cell 127:607–619PubMed
90.
Castellani P et al (1994) The fibronectin isoform containing the ED-B oncofetal domain: a marker of angiogenesis. Int J Cancer 59:612–618PubMed
91.
Castellani P et al (2002) Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol 161:1695–1700PubMed
92.
D’Ovidio MC et al (1998) Intratumoral microvessel density and expression of ED-A/ED-B sequences of fibronectin in breast carcinoma. Eur J Cancer 34:1081–1085PubMed
93.
Inufusa H et al (1995) Localization of oncofetal and normal fibronectin in colorectal cancer. Correlation with histologic grade, liver metastasis, and prognosis. Cancer 75:2802–2808PubMed
94.
Kaczmarek J et al (1994) Distribution of oncofetal fibronectin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 59:11–16PubMed
95.
Lohi J et al (1995) Tenascin and fibronectin isoforms in human renal cell carcinomas, renal cell carcinoma cell lines and xenografts in nude mice. Int J Cancer 63:442–449PubMed
96.
Kosmehl H et al (1999) Distribution of laminin and fibronectin isoforms in oral mucosa and oral squamous cell carcinoma. Br J Cancer 81:1071–1079PubMed
97.
Matsumoto E et al (1999) Expression of fibronectin isoforms in human breast tissue: production of extra domain A +/extra domain B + by cancer cells and extra domain A + by stromal cell. Jap J Cancer Res 90:320–325
98.
Oyama F et al (1989) Deregulation of alternative splicing of fibronectin pre-mRNA in malignant human liver tumors. J Biol Chem 264:10331–10334PubMed
99.
Oyama F et al (1990) Oncodevelopmental regulation of the alternative splicing of fibronectin pre-messenger RNA in human lung tissues. Cancer Res 50:1075–1078PubMed
100.
Pujuguet P et al (1996) Expression of fibronectin ED-A + and ED-B + isoforms by human and experimental colorectal cancer. Contribution of cancer cells and tumor-associated myofibroblasts. Am J Pathol 148:579–592PubMed
101.
Scarpino S et al (1999) Expression of EDA/EDB isoforms of fibronectin in papillary carcinoma of the thyroid. J Pathol 188:163–167PubMed
102.
Ohnishi T et al (1998) Role of fibronectin-stimulated tumor cell migration in glioma invasion in vivo: clinical significance of fibronectin and fibronectin receptor expressed in human glioma tissues. Clin Exp Metastasis 16:729–741PubMed
103.
Astrof S et al (2004) Direct test of potential roles of EIIIA and EIIIB alternatively spliced segments of fibronectin in physiological and tumor angiogenesis. Mol Cell Biol 24:8662–8670PubMed
104.
Ruoslahti E (2002) Specialization of tumour vasculature. Nat Rev Cancer 2:83–90PubMed
105.
Borsi L et al (2002) Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer 102:75–85PubMed
106.
Nilsson F et al (2001) Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice. Cancer Res 61:711–716PubMed
107.
Kaspar M et al (2006) Fibronectin as target for tumor therapy. Int J Cancer 118:1331–1339PubMed
108.
Villa A et al (2008) A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer 122:2405–2413PubMed
109.
Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58–62PubMed
110.
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592–603PubMed
111.
Batchelor TT et al (2007) AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 11:83–95PubMed
Metadata
Title
Fibronectins in vascular morphogenesis
Authors
Sophie Astrof
Richard O. Hynes
Publication date
01-06-2009
Publisher
Springer Netherlands
Published in
Angiogenesis / Issue 2/2009
Print ISSN: 0969-6970
Electronic ISSN: 1573-7209
DOI
https://doi.org/10.1007/s10456-009-9136-6

Other articles of this Issue 2/2009

Angiogenesis 2/2009 Go to the issue

Original Paper

Morphological and molecular aspects of physiological vascular morphogenesis

Review Paper

Molecular differentiation and specialization of vascular beds

Original Paper

Vasculogenesis in infantile hemangioma

Original Paper

Endogenous endothelial cell signaling systems maintain vascular stability

Original Paper

Role of endothelial progenitors and other bone marrow-derived cells in the development of the tumor vasculature

Original Paper

Intussusceptive angiogenesis and its role in vascular morphogenesis, patterning, and remodeling
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits